Results 91 to 100 of about 7,229 (203)

Transmitted drug resistance to rilpivirine among antiretroviral‐naïve patients living with HIV from northern Poland

Journal of the International AIDS Society, 2014
Introduction Rilpivirine (RPV) is a second‐generation non‐nucleoside reverse transcriptase inhibitor (NNRTI) that was recently approved for the treatment of antiretroviral‐naïve individuals with HIV‐1 viral load of
Miłosz Parczewski, Anna Urbańska, Katarzyna Maciejewska, Magdalena Witak‐Jȩdra, Magdalena Leszczyszyn‐Pynka   +4 more
doaj   +1 more source

A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers.

, 2015
Objectives: The HIV NNRTI rilpivirine is being evaluated as a possible agent for HIV pre-exposure prophylaxis. We have recently shown that the NNRTI efavirenz may impair endothelial function assessed as flow-mediated dilation (FMD), but whether this ...
Liu, Ziyue, Gupta, Samir K., Kamendulis, Lisa M., Slaven, James E.   +3 more
core   +1 more source

Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV

Frontiers in Pharmacology
BackgroundThe pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations.Aims and methodsOur population analysis aims to establish ...
Paul Thoueille, Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Eva Choong, François Veuve, Aline Munting, Matthias Cavassini, Dominique Braun, Dominique Braun, Huldrych F. Günthard, Huldrych F. Günthard, Jessy J. Duran Ramirez, Jessy J. Duran Ramirez, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Alexandra Calmy, Marcel Stöckle, Caroline Di Benedetto, Enos Bernasconi, Patrick Schmid, Catia Marzolini, Catia Marzolini, Catia Marzolini, François R. Girardin, François R. Girardin, Thierry Buclin, Laurent A. Decosterd, Monia Guidi, Monia Guidi, Monia Guidi   +33 more
doaj   +1 more source

A New Stability Indicating RP-HPLC Method Development and Validation for the Simultaneous Estimation of Dolutegravir and Rilpivirine in Bulk and its Dosage Forms: Stability indicating analytical method for simultaneous estimation of Dolutegravir and Rilpivirine by RP-HPLC

, 2019
The objective of the work is to develop and validate a new, simple, highly sensitive, stability indicating RPHPLC method for simultaneous estimation of Dolutegravir and Rilpivirine in bulk and its dosage forms.
Ismail, Yusuff, Shaheedha, S. M., Vara Prasad, M.Vijaya, Habeeb, Mohammad   +3 more
core   +1 more source

Cabotegravir and Rilpivirine

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa. [PDF]

Long-acting injectable (LAI) cabotegravir and rilpivirine for HIV treatment and LAI cabotegravir for pre-exposure HIV prophylaxis are being rolled out in a multitude of countries worldwide.
Nicol, Melanie R, Obura, Bonniface, Waitt, Catriona, Laker, Eva, Steulet, Adrian, Cresswell, Fiona V   +5 more
core   +1 more source

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Journal of the International Association of Providers of AIDS Care, 2019
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD, Filippo Del Puente MD, Lucia Taramasso MD, Antonio Di Biagio MD   +3 more
doaj   +1 more source

Dolutegravir/rilpivirine for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2018
Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
Dowers E, Zamora F, Barakat LA, Ogbuagu O   +3 more
doaj  

Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients

Microorganisms
Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) have been incorporated into the treatment of people living with HIV (PLWH), but evidence on their metabolic impact in real-world settings remains limited.
Marta Segura Díaz, Antonio Collado Romacho, Sergio Ferra Murcia   +2 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source